Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Terminated 3Withdrawn 1Unknown 1Recruiting 1

Sponsor Class

OTHER 2OTHER_GOV 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 1

Conditions

Neoplasms 183Breast Neoplasms 174Carcinoma, Non-Small-Cell Lung 173Colorectal Neoplasms 105Stomach Neoplasms 81Pancreatic Neoplasms 79Lung Neoplasms 79Prostatic Neoplasms 77Melanoma 68Neoplasm Metastasis 67Recurrence 66Leukemia, Myeloid, Acute 66Multiple Myeloma 64Ovarian Neoplasms 62Carcinoma, Hepatocellular 62Lymphoma 61Advanced Solid Tumor 61Advanced Solid Tumors 56Solid Tumor 50Uterine Cervical Neoplasms 48Lymphoma, Non-Hodgkin 48Glioblastoma 44Lymphoma, B-Cell 40Leukemia 39Colonic Neoplasms 34Precursor Cell Lymphoblastic Leukemia-Lymphoma 33Head and Neck Neoplasms 33Esophageal Neoplasms 32Urinary Bladder Neoplasms 30Sarcoma 30

Interventions

Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × INDUSTRY × Brain Diseases × Clear all
NCT00906516 2009-05-21

Neuradiab® Combined With Bevacizumab (Avastin) Therapy in Patients With Recurrent Glioblastoma Multiforme

Bradmer Pharmaceuticals Inc.

Phase 2 Unknown
60 enrolled
CNS

Brain Diseases, Brain Neoplasms, Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡